Table 1 Patient characteristics and analyses based on recurrence-free survival status

Age

 ≤ 40

45 (14.5)

11

24.4

34(72.6)

0.431

 40–60

199(64.2)

37

16.6

166(81.2)

 > 60

66 (21.3)

12

18.2

54(77.3)

FIGO clinical stage (2009)

0.002

 I B1

26

3

11.5

23(88.1%)

 I B2

109 (31.9)

15

13.7

94(84.6%)

 II A1

91 (33.1)

18

18.7

74(79.7%)

 II A2

84(7.6)

24

27.4

61(69.3%)

FIGO surgical restage (2018)

< 0.001*

 I

83(26.8)

6

7.2

77(92.5)

  I B1

17(5.5%)

1

5.9

16(94.1%)

  I B2

40(12.9%)

3

7.5

37(92.0%)

  I B3

26(8.4%)

2

7.7

24(92.3%)

 II

101 (32.6)

16

14.1

85(85.1)

  II A1

50(16.1%)

7

12

44(86.9%)

  II A2

29(9.4%)

3

31

27(91.2)

  II B

22(7.1%)

6

27.3

16(72.7%)

 III C1

104 (33.5)

26

25

78(75.7%)

 III C2

22(7.1)

12

54.5

10(42.4%)

Risk factors

< 0.001

 high-risk

145

44

34.5

95(65.5)

 intermediate-risk

165

16

9.1

150(90.9)

Parametrial invasion

< 0.001

 Pos

28(9.0)

19

62.9

9(32.1)

 Neg

282(91.0)

41

16.7

234(83.3)

Positive vaginal margin

0.006

 Pos

17(5.5)

8

47.1

9(52.9)

 Neg

293(94.5)

52

19.1

237(80.9)

No. of LN+

< 0.001

 ≥ 3

44(14.2)

20

52.3

21(47.7)

 1–2

82(26.5)

18

24.4

62(75.6)

0

184(59.3)

22

11.4

163(88.6)

Depth of stromal invasion

0.022

 Deep 1/3

204(65.8)

47

25

153(75)

 Middle 1/3

77(24.8)

11

14.3

66(85.7)

 Superficial 1/3

29(9.4)

2

6.9

27(93.1)

Tumor diameter

< 0.001

 > 4 cm

123(39.7)

40

34.2

81(65.8)

 ≤ 4 cm

187(60.3)

20

11.8

165(88.2)

LVSI

0.029

 Pos

203(65.5)

44

24.6

153(75.4)

 Neg

107(34.5)

16

14

92(86.0)

Nerve invasion

0.161

 Pos

41(13.2)

10

29.3

29(70.7)

 Neg

269(86.8)

50

19.7

216(80.3)

Vaginal invasion

 Yes

110(35.5)

26

23.6

83(75.5)

0.171

 No

200(64.5)

34

17

164(82)

Histological type

0.535

 SCC

265 (85.5)

49

20.4

211(79.6)

 Non-SCC

45 (14.5)

11

24.5

34(75.5)